



150 W 4th Ave
Vancouver, BC V5Y 1G6
T 1. 604.559.9005
abcellera.com

NEWS RELEASE

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

2025-10-07

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

- Truist Securities BioPharma Symposium, November 6, 2025
- Stifel Healthcare Conference, November 11-13, 2025
- Jefferies Global Healthcare Conference, November 18-20, 2025
- Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025

Visit **[AbCellera's Investor Relations website](#)** for additional information.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit **www.abcellera.com**.

Inquiries

Media: Tiffany Chiu; **media@abcellera.com**, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; **partnering@abcellera.com**, +1(604)559-9005

Investor Relations: Peter Ahn; [**ir@abcellera.com**](mailto:ir@abcellera.com), +1(778)729-9116

Source: AbCellera Biologics Inc.